Technology

Our technology enables significant therapeutic improvements for patients, practitioners and societies all over the world.

Our focus and portfolio

Swedish Pharma is dedicated to bring novel therapeutic technologies to life through cutting-edge research and sharp patient focus.

Our current project pipeline relies on our revolutionary bioadhesive patch technology platform that is the result of many years of practical experience and research within the fields of pharmacology, medicine, drug delivery systems, -development and -design. This patch can be sold with, or without, an active pharmaceutical ingredient (API) – opening up for a wide array of desirable therapeutic application opportunities. Our bioadhesive patch has been tested successfully in clinical studies as a vehicle for the generic drug 5ALA in photodynamic therapy (PDT). Swedish Pharma has also developed a pro-drug with substantial potential in PDT.

Intellectual property

Our technologies are patented in Australia with pending applications in US, EU, Brazil (patch) and Canada (pro-drug).

Plaster_surface

.full-width-594fc26594a1b { min-height:100px; padding:100px 0 80px; margin-bottom:0px; background-color:#ffffff; } #background-layer--594fc26594a1b { background-position:left top; background-repeat:repeat; ; } .mk-main-wrapper { display: none; } #theme-page { padding-top:0; } .full-width-594fc26594a1b .mk-fancy-title.pattern-style span, .full-width-594fc26594a1b .mk-blog-view-all { background-color: #ffffff !important; }

Technology capabilities

Three significant capabilities distinguishes our patch technology from that of any of our competitors – making it one of the most versatile patch technologies around.

icon_adhesion_white_530pxSuperior adhesion

The polymer-based bioadhesive enables firm adhesion to wet skin and dry skin, wounds, mucosa, genitals, nails and eyes. Attachment time can be adjusted from hours to several days.

icon_drug_delivery_performance_white_530px
Drug delivery performance

The unique patch structure allows for delivery of one or more water-soluble active pharmaceutical ingredients (API’s) in very high concentrations.

icon_flexibility_white_530px
Product flexibility

The patch properties and manufacturing technique allows for (i) superior application flexibility, (ii) customer-adaption and (iii) dynamic volumes at low cost.

.full-width-594fc26595ce5 { min-height:0px; padding:90px 0 80px; margin-bottom:0px; background-color:#888888; } #background-layer--594fc26595ce5 { background-image:url(http://swedishpharma.com/wp-content/uploads/Swedish-Pharma–lightgrey-polygons-background_2000px.png); background-position:left top; background-repeat:repeat; ; } .mk-main-wrapper { display: none; } #theme-page { padding-top:0; } .full-width-594fc26595ce5 .mk-fancy-title.pattern-style span, .full-width-594fc26595ce5 .mk-blog-view-all { background-color: #888888 !important; }

Core application areas

Swedish Pharma utilizes the versatility in its patch technology to develop applications within two primary application areas.

.full-width-594fc2659701b { min-height:100px; padding:70px 0 0px; margin-bottom:0px; } #background-layer--594fc2659701b { background-position:left top; background-repeat:repeat; ; } .mk-main-wrapper { display: none; } #theme-page { padding-top:0; }

Drug delivery systems (DDS)

The world’s first patch technology that allows for topical, transdermal and transmucosal delivery of water-soluble pharmaceuticals in clinically relevant concentrations. The unique properties of our polymer-based bioadhesive enable large quantities of active pharmaceutical ingredients to be contained and delivered through skin and mucosa, for either topical or systemic treatment.

TECHNOLOGY CAPABILITIES

– Delivery of both hydro- and lipophilic active pharmaceutical ingredients (API’s)
– Delivery of API’s in very high concentrations (significant drug diffusion)
– Firm adhesion to both dry and wet skin, wounds, mucosa, genitals, nails and eyes.
– Non-invasive technology
– Patient-friendly materials that can be altered for specific applications

Advanced wound care (AWC)

The unique polymer-based bioadhesive technology enables firm adhesion to not only wet and dry skin but also wounds, mucosa, genitals, nails and eyes. Our team possesses extensive knowledge and experience in the field of bioadhesives. Depending on customer specific demands, Swedish Pharma can alter shapes, attachment time and material properties at very low cost. The flexibility in our technology and manufacturing process opens up multiple application areas within the wound care sector.

TECHNOLOGY CAPABILITIES

– Firm adhesion to both dry and wet skin, wounds, mucosa, genitals, nails and eyes.
– Patient-friendly materials that can be altered for specific applications
– Shapes and sizes are easily adapted according to customer preferences

.full-width-594fc26597539 { min-height:100px; padding:50px 0 70px; margin-bottom:0px; } #background-layer--594fc26597539 { background-position:left top; background-repeat:repeat; ; } .mk-main-wrapper { display: none; } #theme-page { padding-top:0; }

Focus on drug delivery systems (DDS)

Drug delivery is the process of administering a pharmaceutical compound to achieve a therapeutic effect in humans and animals. Today’s most commonly adopted administration methods include oral delivery and hypodermic injections – to which transdermal drug delivery constitute an attractive alternative. Transdermal patches allow for painless administration, reduction in first-pass metabolism, controlled drug-release and the possibility to relocate

therapy from the hospital to the patient’s home. For many years patch-based transdermal drug delivery have proven successful in the topical delivery of small lipophilic molecules that are able to penetrate the skin’s outer layers. However, a major challenge for transdermal drug delivery technologies has been the incapability to deliver pharmaceuticals that are soluble in water. We have solved this problem.

Research on drug delivery

Our bioadhesive patch technology has successfully been used in clinical studies as a vehicle of 5ALA in photodynamic treatment (PDT) of superficial neoplastic lesions. PDT is an established and growing therapeutic methodology primarily applied in the treatment of mild to moderate actinic keratosis, a pre-cancerous affliction to the skin normally caused by excessive sun exposure. To find out more about our research results and how it could possibly reinvent the way we use PDT in non-melanoma skin cancer treatment – press here.

.full-width-594fc2659835e { min-height:100px; padding:80px 0 80px; margin-bottom:0px; } #background-layer--594fc2659835e { background-image:url(http://swedishpharma.com/wp-content/uploads/Swedish-Pharma-polygon-bg-4000px.png); background-position:center center; background-repeat:no-repeat; background-attachment: fixed;; } .mk-main-wrapper { display: none; } #theme-page { padding-top:0; }

Interested in our technology?

Swedish Pharma is always in search for promising strategic partnership agreements to improve the quality of our own project portfolio or contribute to others. We are interested in collaborating with academic and industrial actors in further vertical research and/or commercial projects. Our approach to different collaboration models is pragmatic and we invite open enquiries.

General enquiries

Mail: Lennart.Lofgren@swedishpharma.com
Phone: +46 (0) 70 – 292 08 16

.full-width-594fc26599626 { min-height:100px; padding:80px 0 80px; margin-bottom:0px; border:1px solid #eaeaea;border-left:none;border-right:none; } #background-layer--594fc26599626 { background-position:left top; background-repeat:repeat; ; } .mk-main-wrapper { display: none; } #theme-page { padding-top:0; }
Contact Us

Send us an email if you have any questions and we'll get back to you.